Literature DB >> 25461345

Sequential use of mifepristone and misoprostol in treatment of early pregnancy failure appears more effective than misoprostol alone: a retrospective study.

Joyce van den Berg1, Johan M van den Bent2, Marcus P Snijders3, Roel de Heus4, Sjors F Coppus2, Frank P Vandenbussche2.   

Abstract

OBJECTIVE: Is treatment of early pregnancy failure (EPF) with sequential use of mifepristone and misoprostol more effective than treatment with misoprostol alone? STUDY
DESIGN: In a retrospective cohort study at the Department of Obstetrics and Gynaecology of the Radboud University Medical Centre, 301 women with early pregnancy failure receiving medical treatment between January 2008 and March 2013 were included. Of these, 199 women were pre-treated with 200mg mifepristone (orally) followed by 2 consecutive doses of 800mcg misoprostol (vaginally) and 102 women were treated with 2 consecutive doses of 800mcg misoprostol (vaginally) alone.
RESULTS: Complete expulsion was achieved in 66.8% of the women treated with a sequential combination of mifepristone and misoprostol versus 54.9% of the women treated with misoprostol alone. The difference in rates of complete expulsion was 11.9% (P<0.05; 95% CI 0.3-23.6%).
CONCLUSIONS: Medical treatment of early pregnancy failure with a sequential combination of mifepristone and misoprostol was more effective than treatment with misoprostol alone. Our findings will have to be confirmed by a large prospective multicentre double blinded-randomized trial.
Copyright © 2014 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  Early pregnancy failure; Mifepristone; Misoprostol

Mesh:

Substances:

Year:  2014        PMID: 25461345     DOI: 10.1016/j.ejogrb.2014.10.010

Source DB:  PubMed          Journal:  Eur J Obstet Gynecol Reprod Biol        ISSN: 0301-2115            Impact factor:   2.435


  5 in total

1.  Comparison of Mifepristone Followed by Misoprostol with Misoprostol Alone for Treatment of Early Pregnancy Failure: A Randomized Double-Blind Placebo-Controlled Trial.

Authors:  Priya Sinha; Amita Suneja; Kiran Guleria; Richa Aggarwal; Neelam B Vaid
Journal:  J Obstet Gynaecol India       Date:  2017-04-22

2.  Mifepristone and misoprostol versus misoprostol alone for uterine evacuation after early pregnancy failure: study protocol for a randomized double blinded placebo-controlled comparison (Triple M Trial).

Authors:  Joyce van den Berg; Charlotte C Hamel; Marcus P Snijders; Sjors F Coppus; Frank P Vandenbussche
Journal:  BMC Pregnancy Childbirth       Date:  2019-11-27       Impact factor: 3.007

3.  Mifepristone followed by misoprostol compared with placebo followed by misoprostol as medical treatment for early pregnancy loss (the Triple M trial): A double-blind placebo-controlled randomised trial.

Authors:  Charlotte Hamel; Sjors Coppus; Joyce van den Berg; Esther Hink; Jacoba van Seeters; Paul van Kesteren; Ashley Merién; Bas Torrenga; Rafli van de Laar; Josien Terwisscha van Scheltinga; Ingrid Gaugler-Senden; Peppino Graziosi; Minouche van Rumste; Ewka Nelissen; Frank Vandenbussche; Marcus Snijders
Journal:  EClinicalMedicine       Date:  2021-01-06

4.  Economic evaluation of a randomized controlled trial comparing mifepristone and misoprostol with misoprostol alone in the treatment of early pregnancy loss.

Authors:  Charlotte C Hamel; Marcus P L M Snijders; Sjors F P J Coppus; Frank P H A Vandenbussche; Didi D M Braat; Eddy M M Adang
Journal:  PLoS One       Date:  2022-02-09       Impact factor: 3.240

5.  Mifepristone and misoprostol versus misoprostol alone for the management of missed miscarriage (MifeMiso): a randomised, double-blind, placebo-controlled trial.

Authors:  Justin J Chu; Adam J Devall; Leanne E Beeson; Pollyanna Hardy; Versha Cheed; Yongzhong Sun; Tracy E Roberts; C Okeke Ogwulu; Eleanor Williams; Laura L Jones; Jenny H La Fontaine Papadopoulos; Ruth Bender-Atik; Jane Brewin; Kim Hinshaw; Meenakshi Choudhary; Amna Ahmed; Joel Naftalin; Natalie Nunes; Abigail Oliver; Feras Izzat; Kalsang Bhatia; Ismail Hassan; Yadava Jeve; Judith Hamilton; Shilpa Deb; Cecilia Bottomley; Jackie Ross; Linda Watkins; Martyn Underwood; Ying Cheong; Chitra S Kumar; Pratima Gupta; Rachel Small; Stewart Pringle; Frances Hodge; Anupama Shahid; Ioannis D Gallos; Andrew W Horne; Siobhan Quenby; Arri Coomarasamy
Journal:  Lancet       Date:  2020-08-24       Impact factor: 79.321

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.